{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:58:55Z","timestamp":1790683135104,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100008884","name":"Edward P. Evans Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008884","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA008748"],"award-info":[{"award-number":["P30CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA247749"],"award-info":[{"award-number":["P50CA247749"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA171963"],"award-info":[{"award-number":["P50CA171963"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["PO1CA101937"],"award-info":[{"award-number":["PO1CA101937"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA237263"],"award-info":[{"award-number":["R01CA237263"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA248526"],"award-info":[{"award-number":["R01CA248526"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Genet"],"DOI":"10.1038\/s41588-026-02752-2","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T09:02:40Z","timestamp":1790586160000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Germline homologous recombination deficiency influences TP53-mutant clonal hematopoiesis fitness during platinum and PARP inhibitor treatment"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1466-4604","authenticated-orcid":false,"given":"Jeremy T.","family":"Baeten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3250-9626","authenticated-orcid":false,"given":"Irenaeus C. C.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Moukarzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3166-4355","authenticated-orcid":false,"given":"Giulia E. M.","family":"Petrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6365-1888","authenticated-orcid":false,"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2918-8601","authenticated-orcid":false,"given":"Duc","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0867-453X","authenticated-orcid":false,"given":"Jacob","family":"Tabs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imene","family":"Tabet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumedha","family":"Agashe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9903-3738","authenticated-orcid":false,"given":"Elaheh","family":"Nasrollahzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7049-0039","authenticated-orcid":false,"given":"Ankush","family":"Vasireddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minal","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konrad H.","family":"Stopsack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip W.","family":"Kantoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0467-3064","authenticated-orcid":false,"given":"Weiyin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7323-9894","authenticated-orcid":false,"given":"Armel L.","family":"Batchi-Bouyou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1829-1972","authenticated-orcid":false,"given":"J. Scott","family":"Beeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5505-5775","authenticated-orcid":false,"given":"Griffen","family":"Mustion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8494-732X","authenticated-orcid":false,"given":"Paul","family":"Pharoah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5738-6683","authenticated-orcid":false,"given":"James","family":"Brenton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Offit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6661-8733","authenticated-orcid":false,"given":"Bob","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wassim","family":"Abida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6070-2413","authenticated-orcid":false,"given":"Alison M.","family":"Schram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9927-1270","authenticated-orcid":false,"given":"Britta","family":"Weigelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6921-1581","authenticated-orcid":false,"given":"David","family":"Mutch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Vindigni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Mullen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0276-2899","authenticated-orcid":false,"given":"Carlos","family":"Cruchaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6791-9324","authenticated-orcid":false,"given":"Howard","family":"Scher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7884-1905","authenticated-orcid":false,"given":"Ross","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1709-8983","authenticated-orcid":false,"given":"Elli","family":"Papaemmanuil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6538-9705","authenticated-orcid":false,"given":"Mitchell J.","family":"Machiela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Cadoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3170-7581","authenticated-orcid":false,"given":"Daniel C.","family":"Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6584-3357","authenticated-orcid":false,"given":"Kelly L.","family":"Bolton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"2752_CR1","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1158\/1078-0432.CCR-20-2766","volume":"27","author":"CY Chan","year":"2021","unstructured":"Chan, C. Y., Tan, K. V. & Cornelissen, B. PARP inhibitors in cancer diagnosis and therapy. Clin. Cancer Res. 27, 1585\u20131594 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2752_CR2","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","volume":"18","author":"E Pujade-Lauraine","year":"2017","unstructured":"Pujade-Lauraine, E. et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 18, 1274\u20131284 (2017).","journal-title":"Lancet Oncol."},{"key":"2752_CR3","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1158\/1078-0432.CCR-18-1891","volume":"25","author":"NC Turner","year":"2019","unstructured":"Turner, N. C. et al. A phase II study of talazoparib after platinum or cytotoxic nonplatinum regimens in patients with advanced breast cancer and germline BRCA1\/2 mutations (ABRAZO). Clin. Cancer Res. 25, 2717\u20132724 (2019).","journal-title":"Clin. Cancer Res."},{"key":"2752_CR4","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrc.2017.60","volume":"17","author":"M McNerney","year":"2017","unstructured":"McNerney, M., Godley, L. & Le Beau, M. Therapy-related myeloid neoplasms: when genetics and environment collide. Nat. Rev. Cancer 17, 513\u2013527 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"2752_CR5","doi-asserted-by":"publisher","first-page":"6385","DOI":"10.3390\/cancers13246385","volume":"13","author":"CM Csizmar","year":"2021","unstructured":"Csizmar, C. M., Saliba, A. N., Swisher, E. M. & Kaufmann, S. H. PARP inhibitors and myeloid neoplasms: a double-edged sword. Cancers 13, 6385 (2021).","journal-title":"Cancers"},{"key":"2752_CR6","doi-asserted-by":"publisher","first-page":"5548","DOI":"10.1200\/JCO.2018.36.15_suppl.5548","volume":"36","author":"J Korach","year":"2018","unstructured":"Korach, J. Incidence of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients (pts) with a germline (g) BRCA mutation (m) and platinum-sensitive relapsed ovarian cancer (PSR OC) receiving maintenance olaparib in SOLO2: impact of prior lines of platinum therapy. J. Clin. Oncol. 36, 5548 (2018).","journal-title":"J. Clin. Oncol."},{"key":"2752_CR7","doi-asserted-by":"publisher","first-page":"5211","DOI":"10.1158\/1078-0432.CCR-22-1622","volume":"28","author":"V Marmouset","year":"2022","unstructured":"Marmouset, V. et al. Therapy-related myeloid neoplasms following PARP inhibitors: real-life experience. Clin. Cancer Res. 28, 5211\u20135220 (2022).","journal-title":"Clin. Cancer Res."},{"key":"2752_CR8","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/nature13968","volume":"518","author":"TN Wong","year":"2015","unstructured":"Wong, T. N. et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature 518, 552\u2013555 (2015).","journal-title":"Nature"},{"key":"2752_CR9","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/S1470-2045(16)30626-X","volume":"18","author":"K Takahashi","year":"2017","unstructured":"Takahashi, K. et al. Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. Lancet Oncol. 18, 100\u2013111 (2017).","journal-title":"Lancet Oncol."},{"key":"2752_CR10","doi-asserted-by":"publisher","unstructured":"Bolton, K. L. et al. Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nat. Genet. https:\/\/doi.org\/10.1038\/s41588-020-00710-0 (2020).","DOI":"10.1038\/s41588-020-00710-0"},{"key":"2752_CR11","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1158\/1078-0432.CCR-24-3683","volume":"31","author":"D Fandrei","year":"2025","unstructured":"Fandrei, D. et al. Clonal evolution of PPM1D mutations in the spectrum of myeloid disorders. Clin. Cancer Res. 31, 2241\u20132253 (2025).","journal-title":"Clin. Cancer Res."},{"key":"2752_CR12","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1101\/gad.1291305","volume":"15","author":"X Lu","year":"2005","unstructured":"Lu, X., Nannenga, B. & Donehower, L. A. PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. Genes Dev. 15, 1162\u20131174 (2005).","journal-title":"Genes Dev."},{"key":"2752_CR13","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.stem.2018.10.004","volume":"23","author":"JI Hsu","year":"2018","unstructured":"Hsu, J. I. et al. PPM1D mutations drive clonal hematopoiesis in response to cytotoxic chemotherapy. Cell Stem Cell 23, 700\u2013713 (2018).","journal-title":"Cell Stem Cell"},{"key":"2752_CR14","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.canlet.2020.09.016","volume":"497","author":"F Neizer-Ashun","year":"2021","unstructured":"Neizer-Ashun, F. & Bhattacharya, R. Reality CHEK: understanding the biology and clinical potential of CHK1. Cancer Lett. 497, 202\u2013211 (2021).","journal-title":"Cancer Lett."},{"key":"2752_CR15","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41586-022-04785-z","volume":"606","author":"MA Fabre","year":"2022","unstructured":"Fabre, M. A. The longitudinal dynamics and natural history of clonal haematopoiesis. Nature 606, 335\u2013342 (2022).","journal-title":"Nature"},{"key":"2752_CR16","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1371\/journal.pcbi.0030225","volume":"3","author":"N Beerenwinkel","year":"2007","unstructured":"Beerenwinkel, N. Genetic progression and the waiting time to cancer. PLoS Comput. Biol. 3, 225 (2007).","journal-title":"PLoS Comput. Biol."},{"key":"2752_CR17","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.jmoldx.2024.03.007","volume":"26","author":"T Mack","year":"2024","unstructured":"Mack, T. Cost-effective and scalable clonal hematopoiesis assay provides insight into clonal dynamics. J. Mol. Diagn. 26, 563\u2013573 (2024).","journal-title":"J. Mol. Diagn."},{"key":"2752_CR18","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1158\/1541-7786.MCR-15-0191-T","volume":"13","author":"TA Hopkins","year":"2015","unstructured":"Hopkins, T. A. et al. Mechanistic dissection of PARP1 trapping and the impact on in vivo tolerability and efficacy of PARP inhibitors. Mol. Cancer Res. 13, 1465\u20131477 (2015).","journal-title":"Mol. Cancer Res."},{"key":"2752_CR19","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/s41586-018-0321-x","volume":"559","author":"PR Loh","year":"2018","unstructured":"Loh, P. R., Genovese, G. & Handsaker, R. E. Insights into clonal haematopoiesis from 8,342 mosaic chromosomal alterations. Nature 559, 350\u2013355 (2018).","journal-title":"Nature"},{"key":"2752_CR20","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41586-020-2426-2","volume":"584","author":"C Terao","year":"2020","unstructured":"Terao, C., Suzuki, A. & Momozawa, Y. Chromosomal alterations among age-related haematopoietic clones in Japan. Nature 584, 130\u2013135 (2020).","journal-title":"Nature"},{"key":"2752_CR21","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2004.11.006","volume":"119","author":"GA Lang","year":"2004","unstructured":"Lang, G. A. et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119, 861\u2013872 (2004).","journal-title":"Cell"},{"key":"2752_CR22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/BF00262732","volume":"21","author":"ZH Siddik","year":"1988","unstructured":"Siddik, Z. H., Jones, M., Boxall, F. E. & Harrap, K. R. Comparative distribution and excretion of carboplatin and cisplatin in mice. Cancer Chemother. Pharmacol. 21, 19\u201324 (1988).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"2752_CR23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-141091","volume":"136","author":"T Ahmed","year":"2020","unstructured":"Ahmed, T. et al. Mutant TRP53-R172H has gain-of-function or dominant-negative effects in response to different hematopoietic stressors in mice. Blood 136, 0006-4971 (2020).","journal-title":"Blood"},{"key":"2752_CR24","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/path.2124","volume":"211","author":"A McCarthy","year":"2007","unstructured":"McCarthy, A. et al. A mouse model of basal-like breast carcinoma with metaplastic elements. J. Pathol. 211, 389\u2013398 (2007).","journal-title":"J. Pathol."},{"key":"2752_CR25","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1242\/dev.01558","volume":"132","author":"M Stadtfeld","year":"2005","unstructured":"Stadtfeld, M. & Graf, T. Assessing the role of hematopoietic plasticity for endothelial and hepatocyte development by non-invasive lineage tracing. Development 132, 203\u2013213 (2005).","journal-title":"Development"},{"key":"2752_CR26","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1038\/s41588-025-02250-x","volume":"57","author":"J Liu","year":"2025","unstructured":"Liu, J. et al. Germline genetic variation impacts clonal hematopoiesis landscape and progression to malignancy. Nat. Genet. 57, 1872\u20131880 (2025).","journal-title":"Nat. Genet."},{"key":"2752_CR27","doi-asserted-by":"publisher","unstructured":"Franch-Exp\u00f3sito, S. et al. Associations between cancer predisposition mutations and clonal hematopoiesis in patients with solid tumors. JCO Precis. Oncol. https:\/\/doi.org\/10.1200\/PO.23.00070 (2023).","DOI":"10.1200\/PO.23.00070"},{"key":"2752_CR28","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1038\/s41375-024-02253-3","volume":"38","author":"CM Arends","year":"2024","unstructured":"Arends, C. M., Kopp, K. & Hablesreiter, R. Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer. Leukemia 38, 1378\u20131389 (2024).","journal-title":"Leukemia"},{"key":"2752_CR29","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1182\/bloodadvances.2025018031","volume":"10","author":"T Badar","year":"2026","unstructured":"Badar, T. et al. Spectrum, prevalence, and clinical correlates of PPM1D mutations in patients with clonal hematopoiesis and clonal cytopenias. Blood Adv. 10, 1746\u20131755 (2026).","journal-title":"Blood Adv."},{"key":"2752_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6496","volume":"5","author":"S Pathania","year":"2014","unstructured":"Pathania, S. et al. BRCA1 haploinsufficiency for replication stress suppression in primary cells. Nat. Commun. 5, 5496 (2014).","journal-title":"Nat. Commun."},{"key":"2752_CR31","first-page":"4842","volume":"61","author":"ME Moynahan","year":"2001","unstructured":"Moynahan, M. E., Cui, T. Y. & Jasin, M. Homology-directed dna repair, mitomycin-C resistance, and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res. 61, 4842\u20134850 (2001).","journal-title":"Cancer Res."},{"key":"2752_CR32","doi-asserted-by":"publisher","unstructured":"Lim, P. X., Zaman, M., Feng, W. & Jasin, M. BRCA2 promotes genomic integrity and therapy resistance primarily through its role in homology-directed repair. Mol. Cell https:\/\/doi.org\/10.1016\/j.molcel.2023.12.025 (2024).","DOI":"10.1016\/j.molcel.2023.12.025"},{"key":"2752_CR33","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.molcel.2018.08.016","volume":"72","author":"D Billing","year":"2018","unstructured":"Billing, D. et al. The BRCT domains of the BRCA1 and BARD1 tumor suppressors differentially regulate homology-directed repair and stalled fork protection. Mol. Cell 72, 127\u2013139 (2018).","journal-title":"Mol. Cell"},{"key":"2752_CR34","doi-asserted-by":"publisher","first-page":"5844","DOI":"10.1182\/blood-2023-188898","volume":"142","author":"M Sidenna","year":"2023","unstructured":"Sidenna, M., Al Sulaiman, R., Ben-Omran, T., Bujassoum, S. & Gameil, A. Li-Fraumeni syndrome: the two faces of a coin in myeloid malignancies. Blood 142, 5844 (2023).","journal-title":"Blood"},{"key":"2752_CR35","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1001\/jamaoncol.2021.4664","volume":"7","author":"TT Kwan","year":"2021","unstructured":"Kwan, T. T., Oza, A. M. & Tinker, A. V. Preexisting TP53-variant clonal hematopoiesis and risk of secondary myeloid neoplasms in patients with high-grade ovarian cancer treated with rucaparib. JAMA Oncol. 7, 1772\u20131781 (2021).","journal-title":"JAMA Oncol."},{"key":"2752_CR36","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btae121","volume":"40","author":"ICC Chan","year":"2024","unstructured":"Chan, I. C. C. et al. ArCH: improving the performance of clonal hematopoiesis variant calling and interpretation. Bioinformatics 40, btae121 (2024).","journal-title":"Bioinformatics"},{"key":"2752_CR37","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nbt.2514","volume":"31","author":"K Cibulskis","year":"2013","unstructured":"Cibulskis, K., Lawrence, M. & Carter, S. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213\u2013219 (2013).","journal-title":"Nat. Biotechnol."},{"key":"2752_CR38","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkw227","volume":"44","author":"Z Lai","year":"2016","unstructured":"Lai, Z. et al. VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research. Nucleic Acids Res. 44, e108 (2016).","journal-title":"Nucleic Acids Res."},{"key":"2752_CR39","doi-asserted-by":"publisher","first-page":"11189","DOI":"10.1093\/nar\/gks918","volume":"40","author":"A Wilm","year":"2012","unstructured":"Wilm, A. et al. LoFreq: a sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets. Nucleic Acids Res. 40, 11189\u201311201 (2012).","journal-title":"Nucleic Acids Res."},{"key":"2752_CR40","doi-asserted-by":"publisher","unstructured":"Poplin, R. et al. A universal SNP and small-indel variant caller using deep neural networks. Nat. Biotechnol. https:\/\/doi.org\/10.1038\/nbt.4235 (2018).","DOI":"10.1038\/nbt.4235"},{"key":"2752_CR41","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405\u2013424 (2015).","journal-title":"Genet. Med."},{"key":"2752_CR42","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1152\/ajprenal.00512.2015","volume":"310","author":"CN Sharp","year":"2016","unstructured":"Sharp, C. N. et al. Repeated administration of low-dose cisplatin in mice induces fibrosis. Am. J. Physiol.-Ren. Physiol. 310, 560\u2013568 (2016).","journal-title":"Am. J. Physiol.-Ren. Physiol."},{"key":"2752_CR43","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1172\/JCI70196","volume":"126","author":"R Drost","year":"2016","unstructured":"Drost, R. et al. BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1. J. Clin. Invest. 126, 2903\u20132918 (2016).","journal-title":"J. Clin. Invest."},{"key":"2752_CR44","doi-asserted-by":"publisher","first-page":"5003","DOI":"10.1158\/1078-0432.CCR-13-1391","volume":"19","author":"Y Shen","year":"2013","unstructured":"Shen, Y. et al. BMN 673, a novel and highly potent PARP1\/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin. Cancer Res. 19, 5003\u20135015 (2013).","journal-title":"Clin. Cancer Res."},{"key":"2752_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43446-1","volume":"14","author":"JJ Krais","year":"2023","unstructured":"Krais, J. J. et al. Genetic separation of Brca1 functions reveal mutation-dependent Pol\u03b8 vulnerabilities. Nat. Commun. 14, 7714 (2023).","journal-title":"Nat. Commun."},{"key":"2752_CR46","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abq0648","volume":"8","author":"A Meroni","year":"2022","unstructured":"Meroni, A. et al. NEDDylated cullin 3 mediates the adaptive response to topoisomerase 1 inhibitors. Sci. Adv. 8, eabq0648 (2022).","journal-title":"Sci. Adv."},{"key":"2752_CR47","doi-asserted-by":"publisher","unstructured":"Chan, I. Germline homologous recombination deficiency influences TP53-mutant clonal hematopoiesis fitness during platinum and PARP inhibitor treatment. Zenodo https:\/\/doi.org\/10.5281\/zenodo.21418927 (2026).","DOI":"10.5281\/zenodo.21418927"}],"container-title":["Nature Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41588-026-02752-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41588-026-02752-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41588-026-02752-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:20:52Z","timestamp":1790680852000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41588-026-02752-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":47,"alternative-id":["2752"],"URL":"https:\/\/doi.org\/10.1038\/s41588-026-02752-2","relation":{},"ISSN":["1061-4036","1546-1718"],"issn-type":[{"value":"1061-4036","type":"print"},{"value":"1546-1718","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"5 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.L.B. receives research funding and serves on the medical advisory board of Servier Pharmaceuticals. B.W. reports research funding from REPARE Therapeutics and SAGA Diagnostics paid to the institution, and has an immediate family member employed by AstraZeneca. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}